Cilcare Secures Funding to Advance Clinical Trials for Cochlear Synaptopathy Treatment
Cilcare raised €40 million in Series A funding to initiate two clinical trials in 2025 for treatment of cochlear synaptopathy.
Cilcare raised €40 million in Series A funding to initiate two clinical trials in 2025 for treatment of cochlear synaptopathy.
Once you start to lose your hearing, you can’t get it back. But what if you could prevent...
This includes multiple presentations demonstrating the therapeutic potential of OTO-413, an otic formulation of brain-derived neurotrophic factor (BDNF), for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.